Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by fredgoodwinsonon Jan 09, 2020 5:58am
155 Views
Post# 30533411

COULD THEY BE???

COULD THEY BE???

Could they be actually be using the tortuous (and torturous) initiation of this Trial to our advantage?

 

A consequence of insisting on a sufficient sample (say 25) before announcing 3-month complete responses following such a tapered lead-in will be that a significant number of those 25 (say 10) will by then also have received their second treatment.

 

Now let`s say that some of those 10 (we all hope that it will be none but it is possible that there may be some) fail to achieve a CR at 3 months`or achieve their CR at 3 months but without the attendant ’no clinical evidence or presence of disease’ and the second treatment delivers them the knockout blow.

 

There could then be an addendum to the 3 month results that might read something like this:

 

‘The first 10 patients in this trial have now received their second treatment and of the x number who still had a detectable presence of cancer at 3 months only y number/none now do so.’

 

There is already precedent to allow pre 90-day publication of second treatment status and that is the ann of Monday the 18th of April 2018 an extract from which read as follows:

 

‘The sixth patient’s 90-day cystoscopy analysis will be completed in May 2018 to rule out recurrent NMIBC. To date, the patient has shown no clinical evidence or presence of disease’

 

Was this whole long slow start deliberately contrived so as to conflate the benefits of the second treatment with the CR Results ?

 

Now that would be clever - but then they are quite clever.

 
Bullboard Posts